These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 25394092)

  • 1. Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.
    Dickinson L; Winston A; Boffito M; Khoo S; Back D; Siccardi M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19586. PubMed ID: 25394092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    De Nicolò A; Calcagno A; Motta I; De Vivo E; D'Avolio A; Di Perri G; Wiesner L; Ebrahim IE; Maartens G; Orrell C; McIlleron H
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0013622. PubMed ID: 35583344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.
    Dickinson L; Winston A; Boffito M; Khoo S; Back D; Siccardi M
    J Antimicrob Chemother; 2016 Apr; 71(4):1041-5. PubMed ID: 26712906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.
    Lanzafame M; Lattuada E; Rigo F; Hill A; Vento S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19822. PubMed ID: 25397566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
    Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
    Abdalla S; Compagnucci A; Riault Y; Chan MK; Bamford A; Nolan A; Ramos JT; Constant V; Nguyen T-N; Zheng Y; Tréluyer J-M; Froelicher-Bournaud L; Neveux N; Saidi Y; Cressey TR; Hirt D;
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0100423. PubMed ID: 38092664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
    Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
    Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).
    Prins HAB; Zino L; Svensson EM; Verbon A; de Bree GJ; Prins JM; Reiss P; Burger DM; Rokx C; Colbers A;
    Int J Antimicrob Agents; 2023 Jan; 61(1):106697. PubMed ID: 36470510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
    Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
    Tashima K; Crofoot G; Tomaka FL; Kakuda TN; Brochot A; Vanveggel S; Opsomer M; Garner W; Margot N; Custodio JM; Fordyce MW; Szwarcberg J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19772. PubMed ID: 25397516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor.
    Lin KY; Cheng CY; Yang CJ; Tsai MS; Hsieh SM; Sun HY; Sheng WH; Chen MY; Chang SY; Cheng SH; Hung CC
    J Infect Chemother; 2014 Aug; 20(8):465-70. PubMed ID: 24855915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
    Baroncelli S; Villani P; Galluzzo CM; Cavalli A; Volpe A; Francisci D; Vivarelli A; Sozio F; Tedeschi S; Cirioni O; Sighinolfi L; Cusato M; Pirillo MF; Weimer LE; Fragola V; Parruti G; Regazzi M; Floridia M
    Ther Drug Monit; 2013 Dec; 35(6):785-90. PubMed ID: 24061444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.